FHIR © HL7.org  |  Server Home  |  FHIR Server FHIR Server 3.7.21  |  FHIR Version n/a  User: [n/a]

35754511000001107: Daxas 250microgram tablets (AstraZeneca UK Ltd) (product)

Status: current, Not sufficiently defined by necessary conditions definition status. Date: 03-Oct 2018. Module: SNOMED CT United Kingdom drug extension module

Descriptions:

Id Description Lang Type Status Case? Module
109956301000001115 Daxas 250microgram tablets (AstraZeneca UK Ltd) (product) en Fully specified name Active Entire term case sensitive SNOMED CT United Kingdom drug extension module
109956401000001111 Daxas 250microgram tablets (AstraZeneca UK Ltd) en Synonym Active Entire term case sensitive SNOMED CT United Kingdom drug extension module

0 descendants.

Expanded Value Set

Outbound Relationships Type Target Active Characteristic Refinability Group Values
Daxas 250microgram tablets (AstraZeneca UK Ltd) Has excipient Excipient not declared true Inferred relationship Existential restriction modifier
Daxas 250microgram tablets (AstraZeneca UK Ltd) Has NHS dm+d (dictionary of medicines and devices) controlled drug category Controlled drug category No Controlled Drug Status true Inferred relationship Existential restriction modifier
Daxas 250microgram tablets (AstraZeneca UK Ltd) Has NHS dm+d (dictionary of medicines and devices) additional monitoring indicator EMA (European Medicines Agency) monitoring true Inferred relationship Existential restriction modifier
Daxas 250microgram tablets (AstraZeneca UK Ltd) Has NHS dm+d (dictionary of medicines and devices) AMP (actual medicinal product) availability restriction indicator NHS dm+d (dictionary of medicines and devices) AMP (actual medicinal product) availability restriction none true Inferred relationship Existential restriction modifier
Daxas 250microgram tablets (AstraZeneca UK Ltd) Is a Roflumilast 250microgram tablets true Inferred relationship Existential restriction modifier
Daxas 250microgram tablets (AstraZeneca UK Ltd) Has active ingredient Roflumilast true Inferred relationship Existential restriction modifier
Daxas 250microgram tablets (AstraZeneca UK Ltd) VMP prescribing status (attribute) VMP valid as a prescribable product true Inferred relationship Existential restriction modifier
Daxas 250microgram tablets (AstraZeneca UK Ltd) VMP non-availability indicator Available true Inferred relationship Existential restriction modifier
Daxas 250microgram tablets (AstraZeneca UK Ltd) Has specific active ingredient Roflumilast true Inferred relationship Existential restriction modifier
Daxas 250microgram tablets (AstraZeneca UK Ltd) Has dispensed dose form Tablet true Inferred relationship Existential restriction modifier
Daxas 250microgram tablets (AstraZeneca UK Ltd) Has excipient Lactose false Inferred relationship Existential restriction modifier
Daxas 250microgram tablets (AstraZeneca UK Ltd) Is a Actual medicinal product true Inferred relationship Existential restriction modifier
Daxas 250microgram tablets (AstraZeneca UK Ltd) Is a Daxas true Inferred relationship Existential restriction modifier
Inbound Relationships Type Active Source Characteristic Refinability Group
Daxas 250microgram tablets (AstraZeneca UK Ltd) 28 tablet 2 x 14 tablets Has AMP True Daxas 250microgram tablets (AstraZeneca UK Ltd) Inferred relationship Existential restriction modifier

This concept is not in any reference sets

Back to Start